Roche: results of study for Covid-19 patients

(CercleFinance.com) - Roche says the phase III EMPACTA study showed that Actemra/RoActemra reduced the likelihood of requiring mechanical ventilation in hospitalised patients suffering from COVID-19-associated pneumonia.


EMPACTA is the first global phase III trial to demonstrate the efficacy of Actemra/RoActemra in COVID-19-associated pneumonia.

Patients are 44% less likely to have to go on ventilators or die than patients who received a placebo.

The group said that it intends to share this important data with the FDA and other health authorities worldwide.


Copyright (c) 2020 CercleFinance.com. All rights reserved.